T-cell receptors are the next frontier for human health.
Vcreate uses machine learning to understand and engineer human T-cell receptors (TCRs) that can treat diseases impossible to treat before.
Targeting diseases with precision.
T-cell receptors can detect targets inside of cells undruggable by most therapies.
Our platform helps design high precision TCR-based drugs can destroy target cells while sparing normal cells.
A platform for 100x faster discovery.
The primary bottleneck in the development of T-cell receptor based therapies is the identification of T-cell receptors that activate against disease-specific targets.
Leveraging novel molecular biology and single-cell sequencing, Vcreate’s screening assays can interrogate hundreds of millions of TCR-antigen interactions in a single flask. Compared to other assays like tetramer staining or yeast display, this represents a more than 100x speedup and enables the development of new therapies.
Designing T-cell receptors with AI.
Vcreate leverages the unprecedented datasets generated by our assays to train machine learning algorithms that can design T-cell receptors that activate against a target of interest.
These algorithms allow us to target rare cancer mutations even when they do not exist in our experimental datasets.
Supported by
